Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Introgen Restructures To Ready For Advexin Approval Process

This article was originally published in The Pink Sheet Daily

Executive Summary

New manufacturing unit could profit from pickup in gene-therapy business.

You may also be interested in...



FDA Refuses To File BLA For Cancer Gene Therapy

Advexin setback compounds dicey financial status of developmental company Introgen.

FDA Refuses To File BLA For Cancer Gene Therapy

Advexin setback compounds dicey financial status of developmental company Introgen.

Introgen Files Advexin For Head And Neck Cancer In U.S., EU

Biotech says it hopes to follow the Idec/Rituxan model in bringing oncologic gene therapy to the U.S. market.

Topics

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel